Press releases
2021
13 December, 2021
Egetis intends to submit a marketing authorisation application for Emcitate® to the European Medicines Agency based on existing clinical data
5 November, 2021
Nomination Committee appointed for the 2022 Annual General Meeting in Egetis Therapeutics
4 November, 2021
Interim report January-September 2021
19 August, 2021
Emcitate development program progressing according to plan
19 April, 2021
Egetis Therapeutics appoints Yilmaz Mahshid as new CFO
30 March, 2021
Egetis Therapeutics 2020 annual report published
15 February, 2021
Egetis appoints Dr Kristina Sjöblom Nygren as new CMO
20 January, 2021
Peder Walberg appointed as interim Chief Medical Officer